Platelet function and signaling in diabetes mellitus

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 532-538

  Randriamboavonjy, Voahanginirina ^a   Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Atherothrombosis; Calpain; Chemokines; Diabetes; Platelets redox stress

Indexed keywords

CALPAIN; CHEMOKINE; GROWTH FACTOR; MICRORNA;

DIABETES MELLITUS; ENDOTHELIUM CELL; GENE DELIVERY SYSTEM; HYPERGLYCEMIA; INTRACELLULAR SIGNALING; OXIDATIVE STRESS; PLATELET MICROPARTICLE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CHEMOKINES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; MYOCYTES, SMOOTH MUSCLE; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84864567858     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784639     Document Type: Review

References (96)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
2. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74.
3. Wong WT, Wong SL, Tian XY, Huang Y. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 2010; 55: 300-7.
4. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32: 838-46.
5. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-22.
6. El HM, Rosado JA. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis 2008; 41: 119-23.
7. 2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 2008; 117: 52-60.
8. Rajendran S, Chirkov YY. Platelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target. Cardiovasc Drugs Ther 2008; 22: 193-203.
9. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7: 251-9.
10. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11: 2331-65.
11. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-90.
12. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-4.
13. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
14. Brown AS, Hong Y, de BA, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 802-7.
15. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-11.
16. Bunting S, Moncada S, Vane JR. Antithrombotic properties of vascular endothelium. Lancet 1977; 2: 1075-6.
17. 2+stores. Biochem J 1991; 280 (Pt 3): 783-9.
18. 2+entry in human platelets. Biochem J 1992; 285 (Pt 1): 341-4.
19. Varga-Szabo D, Braun A, Nieswandt B. STIM and Orai in platelet function. Cell Calcium 2011; 50: 270-8.
20. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-9.
21. Randriamboavonjy V, Isaak J, Fromel T, et al. AMPK alpha2 subunit is involved in platelet signaling, clot retraction, and thrombus stability. Blood 2010; 116: 2134-40.
22. Viollet B, Andreelli F, Jorgensen SB, et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003; 111:91-8.
23. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev 2009; 89: 1025-78.
24. Reed GL, Houng AK, Fitzgerald ML. Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion. Blood 1999; 93: 2617-26.
25. Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med 2004; 199: 347-56.
26. Suzuki K, Hata S, Kawabata Y, Sorimachi H. Structure, activation, and biology of calpain. Diabetes 2004; 53 (Suppl 1): S12-S18.
27. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83: 731-801.
28. Kuchay SM, Chishti AH. Calpain-mediated regulation of platelet signaling pathways. Curr Opin Hematol 2007; 14: 249-54.
29. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-95.
30. Schuerholz T, Losche W, Keil O, Friedrich L, Simon TP, Marx G. Acute short-term hyperglycemia impairs platelet receptor expression even in healthy adults in vitro. Med Sci Monit 2008; 14: BR294-BR298.
31. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
32. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 1995; 74: 224-7.
33. Larsen E, Palabrica T, Sajer S, et al. PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15). Cell 1990; 63: 467-74.
34. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: S97-103.
35. Hu H, Li N, Yngen M, Ostenson CG, Wallen NH, Hjemdahl P. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 2: 58-64.
36. Kaplar M, Kappelmayer J, Veszpremi A, Szabo K, Udvardy M. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419-22.
37. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997; 29: 631-5.
38. Monnier VM. Non-enzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990; 45: B105-B111.
39. Gawlowski T, Stratmann B, Ruetter R, et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48: 475-81.
40. Hangaishi M, Taguchi J, Miyata T, et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998; 248: 285-92.
41. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
42. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25: 1401-7.
43. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
44. Abe J, Takahashi M, Ishida M, Lee JD, Berk BC. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J Biol Chem 1997; 272: 20389-94.
45. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 1998; 10: 248-53.
46. 2+entry in human platelets. Cell Signal 2005; 17: 1011-21.
47. Krotz F, Sohn HY, Gloe T, et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002; 100: 917-24.
48. Chlopicki S, Olszanecki R, Janiszewski M, Laurindo FR, Panz T, Miedzobrodzki J. Functional role of NADPH oxidase in activation of platelets. Antioxid Redox Signal 2004; 6: 691-8.
49. Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999-1006.
50. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91: 484-90.
51. Seno T, Inoue N, Gao D, et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001; 103: 399-409.
52. Wachowicz B, Olas B, Zbikowska HM, Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 2002; 13: 175-82.
53. Adachi T, Matsui R, Xu S, et al. Antioxidant improves smooth muscle sarco/endoplasmic reticulum Ca(2+)-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation. Circ Res 2002; 90: 1114-21.
54. Adachi T, Weisbrod RM, Pimentel DR, et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004; 10: 1200-7.
55. Randriamboavonjy V, Badenhoop K, Schmidt H, Geisslinger G, Fisslthaler B, Fleming I. The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. Basic Res Cardiol 2009; 104: 333-40.
56. Falati S, Patil S, Gross PL, et al. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 2006; 107: 535-41.
57. Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001; 97: 1727-32.
58. Fox JE, Austin CD, Reynolds CC, Steffen PK. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-95.
59. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-97.
60. Zwicker JI, Trenor CC 3rd, Furie BC, Furie B. Tissue factorbearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31: 728-33.
61. Tripodi A, Branchi A, Chantarangkul V, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 2011; 31: 165-72.
62. Nakamura M, Mori M, Nakazawa S, et al. Replacement of mcalpain by mu-calpain during maturation of megakaryocytes and possible involvement in platelet formation. Thromb Res 1992; 66: 757-64.
63. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17: 47-58.
64. Tschoepe D, Roesen P, Esser J, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
65. Watala C, Boncler M, Pietrucha T, Trojanowski Z. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 1999; 10: 52-60.
66. Tschope D, Schwippert B, Schettler B, et al. Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur J Clin Invest 1992; 22: 591-8.
67. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164-71.
68. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85.
69. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
70. Seizer P, Gawaz M, May AE. Platelet-monocyte interactions--a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 2008; 15: 1976-80.
71. Giannini S, Falcinelli E, Bury L, et al. Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. Am J Physiol Heart Circ Physiol 2011; 300: H2072-H2079.
72. Xia M, Li G, Ma J, Ling W. Phosphoinositide 3-kinase mediates CD40 ligand-induced oxidative stress and endothelial dysfunction via Rac1 and NADPH oxidase 2. J Thromb Haemost 2010; 8: 397-406.
73. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
74. Cipollone F, Chiarelli F, Davi G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-24.
75. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-71.
76. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
77. Mause SF, von HP, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512-8.
78. Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-61.
79. Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005; 54 Suppl 2: S11-S17.
80. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000; 121: 437-43.
81. Kashiwada K, Nishida W, Hayashi K, et al. Coordinate expression of alpha-tropomyosin and caldesmon isoforms in association with phenotypic modulation of smooth muscle cells. J Biol Chem 1997; 272: 15396-404.
82. Massberg S, Vogt F, Dickfeld T, Brand K, Page S, Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res 2003; 110: 187-94.
83. Sobue K, Hayashi K, Nishida W. Molecular mechanism of phenotypic modulation of smooth muscle cells. Horm Res 1998; 50 Suppl 2: 15-24.
84. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010; 16: 909-14.
85. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283: 15878-83.
86. Li YX, Liu DQ, Zheng C, et al. miR-200a modulate HUVECs viability and migration. IUBMB Life 2011; 63: 553-9.
87. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119: 2634-47.
88. Quintavalle M, Elia L, Condorelli G, Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol 2010; 189:13-22.
89. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
90. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
91. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res 2011; 157: 253-64.
92. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-7.
93. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-6.
94. Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009; 4: e4722.
95. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-46.
96. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30: 111-42.